EU/3/17/1950:

Adenovirus associated viral vector serotype 8 containing the human AIPL1 gene

Overview

On 12 December 2017, orphan designation (EU/3/17/1950) was granted by the European Commission to MeiraGTx UK II Limited, United Kingdom, for adenovirus associated viral vector serotype 8 containing the human AIPL1 gene for the treatment of Leber's congenital amaurosis.

The sponsorship was transferred to MeiraGTx B.V., The Netherlands in May 2019.

The sponsor’s address was updated in July 2021.

Key facts

Active substance
Adenovirus associated viral vector serotype 8 containing the human AIPL1 gene
Intented use
Treatment of Leber's congenital amaurosis
Date of designation
12/12/2017
Orphan designation status
Positive
EU designation number
EU/3/17/1950

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

MeiraGTx B.V.
Paalbergweg 2-4
Amsterdam 
1105 AG
Noord-Holland
Netherlands
tel: +31858000860
e-mail: Janneke.Meulenberg@meiragtx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating